Science news

<<  return

 

A comprehensive meta-analysis of randomized controlled trials in which the smoking cessation drug varenicline (Chantix, Pfizer Inc) was compared with placebo found no evidence of an increased risk for neuropsychiatric adverse events (AEs), including suicide, new research shows.

This meta-analysis found no evidence of an increased risk of suicide or attempted suicide, suicidal ideation, depression, or death with varenicline. These findings provide some reassurance for users and prescribers regarding the neuropsychiatric safety of varenicline. There was evidence that varenicline was associated with a higher risk of sleep problems such as insomnia and abnormal dreams. These side effects, however,are already well recognised.

BMJ2015; 350doi: http://dx.doi.org/10.1136/bmj.h1109(Published 12 March 2015)Cite this as: BMJ 2015;350:h1109